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Abstract
Legionnaires’ disease remains an important cause of mortality
and morbidity worldwide. Disease caused by Legionella pneumo-
phila has been extensively studied, and its clinical characteristics
have been well described. There is, however, little information
on disease caused by Legionella longbeachae, despite its impor-
tance in some countries. We undertook a retrospective review
of culture-positive cases of Legionnaires’ disease in the Canter-
bury region of New Zealand over 10 years, in order to compare
the clinical features and outcomes of Legionnaires’ disease
caused by these two species.
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Legionella species have been recognized as human pathogens
since 1977. Since then, more than 50 species have been iden-
tiﬁed, at least half of which have been associated with human
disease. Despite this, surveillance programmes in Europe [1]
and the USA [2] have consistently shown Legionella pneumo-
phila to be the predominant cause of Legionnaire’s disease,
accounting for 90% or more of cases. Cases caused by
Legionella longbeachae come a distant second or third,
accounting for 5% or less of cases. In contrast, surveillance
data from Australia and New Zealand [3,4] have consistently
shown L. longbeachae to be either the leading cause of
Legionnaires’ disease or a close second to L. pneumophila. A
recent survey of rural Thailand also found L. longbeachae to
be the predominant cause of Legionnaires’ disease there
[5].The clinical features and outcomes of Legionnaires’ dis-
ease caused by L. pneumophila have been extensively studied,
but data on disease caused by L. longbeachae are sparse. A
review by Muder and Yu in 2002 [6] suggested that disease
caused by non-L. pneumophila species was clinically similar to
that caused by L. pneumophila, but occurred mainly in
immunosuppressed patients. This suggestion was based
mainly on data from disease caused by Legionella micdadei
and other non-L. longbeachae species. The Canterbury region
of New Zealand, in common with the rest of Australasia,
experiences a high rate of Legionnaires’ disease caused by
L. longbeachae. We sought to investigate whether the clinical
features and outcomes associated with this were different
from those associated with disease due to L. pneumophila.
From the Canterbury Health Laboratories database, we
identiﬁed all clinical specimens with growth of Legionella spe-
cies from 1998 to 2008 for patients from the Canterbury
region. The case notes were retrospectively reviewed. All
specimens had originated from patients admitted to Christ-
church hospital with a clinical illness consistent with Legion-
naires’ disease. Mortality data were obtained from the
New Zealand National Registry of Births and Deaths. Data
prospectively collected by the local Public Health Unit were
reviewed. Dichotomous and continuous variables were
tested by Fisher’s exact test and t-test, respectively.
Deﬁnitions of hospital-acquired and healthcare-associated
disease were as used in the American Thoracic Society/
Infectious Diseases Society of America guidelines [7]. For
CURB-65 [8] and systemic inﬂammatory response score [9]
criteria, confusion was scored if any mention was made of new
confusion in the admission notes. Other data were derived
from observations and blood tests performed on admission.
We identiﬁed 50 episodes of culture-positive Legionnaires’
disease in 48 unique patients (two patients had two separate
episodes of disease caused by L. longbeachae). L. longbeachae
was identiﬁed in 24 (48%) episodes, L. pneumophila in 20
(40%), and other Legionella species in six (12%). Patient char-
acteristics, including risk factors for immunosuppression and
underlying lung disease, are shown in Table 1. In episodes
where criteria as deﬁned by Cunha [10] could be applied
(adults, no concomitant heart rate-lowering medications, or
arrhythmia and temperature >38.9C), relative bradycardia
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases
RESEARCH NOTE INFECTIOUS DISEASES
was present in 10 of 12 (83%) episodes caused by
L. longbeachae and in eight of 14 (57%) episodes caused by
L. pneumophila (p 0.21). In both groups, effective antibiotics
(any of macrolide, quinolone or rifampicin) were started a
median of 1.0 days after admission. The other admission
details are shown in Table 2. No patients had other potential
pathogens identiﬁed on admission. Among episodes caused
by L. longbeachae, subsequent respiratory specimens from
four patients during the admission yielded the following
organisms: herpes simplex virus, Pseudomonas aeruginosa,
Klebsiella pneumoniae, and Acinetobacter species. Among epi-
sodes caused by L. pneumophila, subsequent specimens from
ﬁve patients yielded the following organisms: Aspergillus
fumigatus, K. pneumoniae, Escherichia coli, Serratia species and
herpes simplex virus. None of these isolates resulted in a
change of treatment.
In the 12 months after discharge, there was one death fol-
lowing an episode caused by L. pneumophila. A 69-year-old
woman with a background of rheumatoid arthritis, interstitial
lung disease and chronic, active hepatitis on long-term azathi-
oprine and prednisone died following an episode of respira-
tory failure of unknown cause 3 months after discharge.
There were four re-admissions following episodes caused by
L. pneumophila (one each of: pneumonia with no identiﬁed
pathogen, cholelilithiasis, atrial ﬁbrillation, and possible sei-
zures) and two following episodes caused by L. longbeachae
(one each of: spontaneously resolving supraventricular tachy-
cardia and left ventricular failure).
To our knowledge, this is the ﬁrst study to compare clini-
cal features, risk factors and outcomes of patients from the
same population hospitalized with Legionnaires’ disease
caused by L. longbeachae and L. pneumophila. It also repre-
sents one of the largest case-series of Legionnaires’ disease
caused by L. longbeachae reported to date.
Canterbury Health Laboratories is the only facility to offer
Legionella culture within the region, and therefore we will have
captured all culture-positive cases. Only culture-proven cases
were included, as species identiﬁcation by serology may be
unreliable, and an equivalent antigen test for L. longbeachae is
unavailable. Previous studies have shown that 4–11% of
300–350 admissions with pneumonia to Christchurch Hospital
are due to Legionella species [11,12]. We therefore estimate
TABLE 1. Patient characteristics
Legionella
longbeachae
Legionella
pneumophila
Episodes, n 24 20
Median age, years (range) 73.2 (51–86) 59.3 (12–89)*
Males, no. (%) 20 (83) 16 (80)
Acquisition, no. (%)
Community 24 (100) 13 (65)
Healthcare-associated 0 5 (25)*
Hospital-acquired 0 2 (10)
International travela 2 (8) 3 (15)
Predisposing factors, no. (%)
Smokerb 5 (21) 6 (30)
Diabetes 3 (13) 1 (5)
Chronic renal impairment 3 (13) 0
Dialysis 0 0
COPD 1 (4) 2 (10)
Liver failure 0 0
Haematological malignancy 4 (17) 2 (10)
Solid organ transplant 1 (4) 0
HIV infection 0 1 (5)
Splenectomy 0 0
Immunosuppresive medicationsc 5 (21) 6 (30)
COPD, chronic obstructive pulmonary disease; HIV, human immunodeﬁciency
virus.
aDuring incubation period prior to ﬁrst symptoms.
bWithin 30 days prior to admission.
cSteroids, ‡5 mg/day of prednisone or equivalent, and/or any other recognized
immunosuppressive medication.
*p <0.05 as compared with episodes caused by L. longbeachae.
TABLE 2. Admission details and outcomes
Legionella
longbeachae
Legionella
pneumophila
Episodes, n 24 20
Season of admission, no. (%)
Summer (December–February) 9 (38) 2 (10)*
Autumn (March–May) 6 (25) 6 (30)
Winter (June–August) 0 4 (20)*
Spring (September–November) 9 (38) 8 (40)
Observations on admission (median)
Temperature 38.9C 39.4C
Heart rate 95/min 102/min
Respiratory rate 20/min 24/min
Severity score at admission
CURB-65 (mean) 2.3 1.6
SIRS (mean) 2.7 2.8
Reported symptoms at admission
Days of symptoms (median) 4 5
Respiratory, no. (%)a 17 (71) 16 (80)
Gastrointestinal, no. (%)b 9 (38) 8 (40)
Confusion, no. (%) 4 (17) 4 (20)
Headache, no. (%) 7 (29) 3 (15)
Myalgia, no. (%) 4 (17) 3 (15)
Laboratory ﬁndings on admission
Anaemia, no. (%) 9 (38) 8 (40)
Thrombocytopenia, no. (%) 2 (8) 7 (35)
Acute renal failure, no. (%)c 10 (42) 6 (30)
Hyponatraemia, no. (%) 13 (54) 13 (65)
Abnormal liver function tests, no. (%)d 19 (88) 17 (89)
Total leukocyte count (mean) 14.1 · 109/L 16.8 · 109/L
Radiology on admission, no. (%)
Lobar consolidation 13 (54) 12 (60)
Multilobar consolidation 9 (38) 3 (15)
Pulmonary inﬁltrates 0 1 (5)
Pleural effusion 2 (8) 2 (10)
Not done 2 (8) 4 (20)
Interventions in ICU
Episodes requiring admission, no. (%) 10 (42) 8 (40)
Days in ICU (mean) 13.0 13.5
Invasive ventilatione 9.6 11
Inotrope supporte 2.0 3.6
Renal replacement therapye 2.3 2.5
Inpatient mortality, no. (%) 5 (21) 5 (25)
Follow-up radiology
Follow-up ﬁlm obtained, no. (%) 13 (54) 8 (40)
Weeks from discharge (median) 6.0 7.9
Persisting changes, no. (%) 4 (31) 2 (25)
ICU, intensive-care unit; SIRS, systemic inﬂammatory response score.
aAny of: cough, shortness of breath, sputum production, haemoptysis, or chest
pain.
bAny of: abdominal pain, vomiting, or diarrhoea.
cCreatinine >120 lmol/L or increase of >30% above baseline.
dResults available for 21 episodes of L. longbeachae and 19 of L. pneumophila.
eMedian days of treatment.
*p <0.05 as compared with cases caused by L. longbeachae.
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that our series represents 11–36% of all cases of Legionnaires’
disease requiring hospitalization over this period.
We found that the clinical features, including markers of
disease severity (CURB-65, systemic inﬂammatory response
score criteria, and intensive-care unit treatment), and out-
comes are broadly similar for disease caused by the two
organisms. The only signiﬁcant differences were in age at
onset, season of admission, and place of acquisition. One
possible explanation is the known association between expo-
sure to potting soils and L. longbeachae infection. Canterbury
has a temperate climate, and gardening activity peaks in the
warmer months. The proportion of the population reporting
participation in gardening also increases with age, being par-
ticularly high in those over 65 years of age [13]. L. pneumo-
phila has been intermittently isolated from the hospital water
systems over this time, increasing its association with health-
care-related infections.
The prevalence of predisposing factors for immunosup-
pression or respiratory disease was not signiﬁcantly different
between the two groups. This contrasts with the situation in
Europe and the USA, where disease caused by L. longbeachae
occurs predominantly or exclusively in immunosuppressed
patients [14–17]. Case-series from Australia [18,19] suggest
that immunosuppression is less apparent in cases seen there,
but none have directly compared with cases of Legionnaires’
disease caused by L. longbeachae disease caused by
L. pneumophila. Whether disease caused by L. longbeachae is
different in Australasia than in Europe and the USA is
unclear. A study by Doyle et al. [20] suggested that strains of
L. longbeachae originating from Australian clinical samples
were more virulent than those from the northern hemi-
sphere in an animal model and in vitro.
Both L. pneumophila and L. longbeachae are important
causes of Legionnaires’ disease in Canterbury, and the clinical
presentation and outcomes associated with these organisms
are broadly similar. This has important implications for the
reliance on urinary antigen testing in the exclusion of Legion-
naires’ disease.
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